Lilly rides Mounjaro, Zepbound to better
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles
EU seals a deal on using profits from frozen Russian assets to help arm Ukraine
BRUSSELS (AP) — European Union countries announced on Tuesday that they have reached an agreement to2024-05-22Thai plastics firm will pay $20 million to settle with U.S. over Iran sanctions violations
WASHINGTON (AP) — A Bangkok -based plastics firm has agreed to pay $20 million to settle with the U.2024-05-22China's BYD adds new dealership in Tokyo
TOKYO, April 19 (Xinhua) -- China's leading electric vehicle (EV) manufacturer BYD added a new showr2024-05-22New York Rangers captain Jacob Trouba may be the most interesting man in hockey, on and off the ice
Jacob Trouba is captain of the best team in the NHL this season, the New York Rangers, one of the ol2024-05-22How major US stock indexes fared Monday, 5/20/2024
U.S. stock indexes drifted to a mixed finish after a quiet day of trading, and the Nasdaq composite2024-05-22House Speaker Mike Johnson risks job to deliver aid to Ukraine
WASHINGTON (AP) — Staring down a decision so consequential it could alter the course of history -- b2024-05-22
atest comment